Pfizer Gets Patent Term Extension for Breast Cancer Combination Treatment
07:04 AM EST, 02/05/2021 (MT Newswires) -- Pfizer (PFE) said early on Friday that it has received a patent term extension in the US for Ibrance, an indication for the treatment of advanced or metastatic breast cancer as part of a combination therapy.
The certificate granted by the US Patent and Trademark Office extends the term by more than four years to March 5, 2027, according to a statement.
The company said Ibrance is currently approved in more than 100 countries and has been prescribed to more than 350,000 patients globally.
Price: 34.93, Change: +0.04, Percent Change: +0.11